A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy.
A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy.
复制标题
DOI：
10.1371/journal.pone.0002318
复制
发表时间：
2008
期刊：
影响因子：
3.7
通讯作者：
Jenkins RB
中科院分区：
文献类型：
--
作者：
Nakagawa T;Kollmeyer TM;Morlan BW;Anderson SK;Bergstralh EJ;Davis BJ;Asmann YW;Klee GG;Ballman KV;Jenkins RB
许多男性在前列腺癌的初始治疗后会出现PSA升高。虽然这些男性中的一些人会出现局部或转移性复发，需要进一步治疗，但其他人没有疾病进展的证据。我们假设，一个表达生物标志物小组可以预测哪些PSA升高的男性将受益于进一步的治疗。采用病例对照设计，检测基因表达与预后的关系。系统性（NSCLC）进展病例是前列腺切除术后PSA复发后5年内发生系统性进展的男性。PSA进展对照组为前列腺切除术后PSA复发但5年内无临床进展证据的匹配男性。使用针对石蜡包埋组织RNA优化的表达阵列，评估了1021个癌症相关基因，包括570个与前列腺癌进展有关的基因。包括来自8个先前报道的标记物组的基因。开发了包含17个基因的系统进展模型。该模型生成的AUC为0.88（95% CI：0.84-0.92）。使用3个先前报告的样本组生成了相似的AUC。在次要分析中，该模型预测前列腺癌死亡（在前列腺癌病例中）和5年后全身进展（在PSA对照中）的终点，风险比分别为2.5和4.7（对数秩p值为0.0007和0.0005）。定位到8 q24的基因在模型中显著富集。特异性基因表达模式与PSA复发后的系统性进展显著相关。基因表达模式的测量可能有助于确定哪些男性可能受益于PSA复发后的额外治疗。
Many men develop a rising PSA after initial therapy for prostate cancer. While some of these men will develop a local or metastatic recurrence that warrants further therapy, others will have no evidence of disease progression. We hypothesized that an expression biomarker panel can predict which men with a rising PSA would benefit from further therapy. A case-control design was used to test the association of gene expression with outcome. Systemic (SYS) progression cases were men post-prostatectomy who developed systemic progression within 5 years after PSA recurrence. PSA progression controls were matched men post-prostatectomy with PSA recurrence but no evidence of clinical progression within 5 years. Using expression arrays optimized for paraffin-embedded tissue RNA, 1021 cancer-related genes were evaluated–including 570 genes implicated in prostate cancer progression. Genes from 8 previously reported marker panels were included. A systemic progression model containing 17 genes was developed. This model generated an AUC of 0.88 (95% CI: 0.84–0.92). Similar AUCs were generated using 3 previously reported panels. In secondary analyses, the model predicted the endpoints of prostate cancer death (in SYS cases) and systemic progression beyond 5 years (in PSA controls) with hazard ratios 2.5 and 4.7, respectively (log-rank p-values of 0.0007 and 0.0005). Genes mapped to 8q24 were significantly enriched in the model. Specific gene expression patterns are significantly associated with systemic progression after PSA recurrence. The measurement of gene expression pattern may be useful for determining which men may benefit from additional therapy after PSA recurrence.
登录
查看更多内容
影响因子：
45.3
作者：
D'Amico, AV;Moul, J;Chen, MH
通讯作者：
Chen, MH
影响因子：
5.8
作者：
Ballman, KV;Grill, DE;Therneau, TM
通讯作者：
Therneau, TM
影响因子：
4.4
作者：
Bibikova, Marina;Chudin, Eugene;Wang-Rodriguez, Jessica
通讯作者：
Wang-Rodriguez, Jessica
影响因子：
15.9
作者：
Glinsky, GV;Glinskii, AB;Gerald, WL
通讯作者：
Gerald, WL
DOI：
10.1016/j.ijrobp.2004.03.013
发表时间：
2004-10-01
影响因子：
7
作者：
Kestin, LL;Vicini, FA;Martinez, AA
通讯作者：
Martinez, AA